Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Evans Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Evans Syndrome. Displaying page 1 of 1.
    EudraCT Number: 2006-000393-76 Sponsor Protocol Number: ZKI-SCT-HAPLO-0106 Start Date*: 2006-10-25
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt am Main
    Full Title: Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical related and non-related donators in pediatric patients with and without malignant systemic diseases.
    Medical condition: Pediatric patients with malignant and non-malignant high-risk diseases, where the allogeneic stem cell transplantation represents the only option for a curative therapy and where an adequate HLA-id...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001640-26 Sponsor Protocol Number: 132151 Start Date*: 2020-04-17
    Sponsor Name:University College London
    Full Title: A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial
    Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-004226-25 Sponsor Protocol Number: 07/O21 Start Date*: 2008-03-28
    Sponsor Name:UCL [...]
    1. UCL
    2. UCL
    3.
    Full Title: Low-dose intravenous immunoglobulin or 0.9% saline in the treatment of trigeminal neuralgia refractory to carbamazepine – a randomized double blind parallel placebo-controlled multicentre trial in ...
    Medical condition: Trigeminal neuralgia is a severe neuropathic facial pain that currently can often not be well controlled pharmacologically. The gold standard for medical treatment remains carbamazepine, which may ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044652 Trigeminal neuralgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007258-75 Sponsor Protocol Number: 20060198 Start Date*: 2008-08-22
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndr...
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). ------------------------------------------------------------------------------ Síndrome Mielodisplásico (SMD) de Riesgo Bajo o Intermedio-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Prematurely Ended) NL (Completed) CZ (Prematurely Ended) IE (Completed) AT (Prematurely Ended) DE (Completed) HU (Completed) BE (Completed) GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001872-54 Sponsor Protocol Number: ARC1779−006 Start Date*: 2009-01-24
    Sponsor Name:Archemix Corp
    Full Title: A Randomized, Double−blind, Placebo−controlled, Clinical Outcome Study of ARC1779 Injection in Patients with Thrombotic Microangiopathy.
    Medical condition: Thrombotic microangiopathy (TMA) disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009731 Coagulation disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011184-36 Sponsor Protocol Number: 08/0169 Start Date*: 2009-07-14
    Sponsor Name:University College London-Joint UCLH/UCL Biomedical (R&D) Unit
    Full Title: A Phase II Randomised, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia.
    Medical condition: Non-Dystrophic Myotonia (NDM). Non-dystrophic myotonias are a group of rare neuromuscular disorders that cause episodes of muscle stiffness (known as myotonia) and paralysis. Predominantly the musc...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029317 Neuromuscular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004623-23 Sponsor Protocol Number: AMO-02-MD-2-003 Start Date*: 2018-11-19
    Sponsor Name:AMO Pharma Ltd
    Full Title: A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents with Congenital Myotonic Dystrophy
    Medical condition: Treatment of child and adolescent congenital myotonic dystrophy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068871 Myotonic dystrophy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10068871 Myotonic dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-012072-28 Sponsor Protocol Number: MO22468 Start Date*: 2009-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio randomizado en fase IIIb de MabThera® (rituximab) agregado a quimioterápia, bendamustina o clorambucilo, en pacientes con leucemia linfática crónica. A randomized Phase IIIb study of MabTh...
    Medical condition: Pacientes con leucemia linfática crónica (LLC) en primera linea o segunda línea (máximo de una línea de tratamiento previa) con necesidad de tratamiento. (En España, solo se incluirán pacientes en ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) FR (Completed) FI (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009357-22 Sponsor Protocol Number: 08/0257 Start Date*: 2009-03-09
    Sponsor Name:University College London
    Full Title: A phase IV randomised, placebo controlled, double-blind, single centre, out-patient trial to investigate the functional benefit of botulinum toxin injections combined with physiotherapy treatment f...
    Medical condition: upper limb spasticity after stroke
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014498 Embolic stroke LLT
    9.1 10019016 Haemorrhagic stroke LLT
    9.1 10023027 Ischaemic stroke NOS LLT
    9.1 10027580 Middle cerebral artery stroke LLT
    9.1 10042244 Stroke LLT
    9.1 10043647 Thrombotic stroke LLT
    9.1 10048863 Hemorrhagic stroke LLT
    9.1 10055221 Ischemic stroke LLT
    9.1 10057613 Thromboembolic stroke LLT
    9.1 10061256 Ischaemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2015-001476-22 Sponsor Protocol Number: 04-30 Start Date*: 2016-02-16
    Sponsor Name:Onconova Therapeutics, Inc.
    Full Title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
    Medical condition: Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) HR (Completed) PL (Prematurely Ended) SE (Completed) BE (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA